Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
17 studies found for:    mesothelioma AND South Carolina
Show Display Options
Rank Status Study
1 Completed Capecitabine in Treating Patients With Malignant Mesothelioma
Condition: Malignant Mesothelioma
Intervention: Drug: capecitabine
2 Active, not recruiting Pemetrexed Disodium and Cisplatin With or Without Cediranib Maleate in Treating Patients With Malignant Pleural Mesothelioma
Conditions: Advanced Malignant Mesothelioma;   Epithelioid Mesothelioma;   Recurrent Malignant Mesothelioma;   Sarcomatoid Mesothelioma
Interventions: Drug: Cediranib Maleate;   Drug: Cisplatin;   Drug: Pemetrexed Disodium;   Other: Placebo
3 Completed S9810: Gemcitabine Plus Cisplatin in Treating Patients With Malignant Mesothelioma of the Pleura That Cannot Be Removed by Surgery
Condition: Malignant Mesothelioma
Intervention: Drug: gemcitabine hydrochloride
4 Completed
Has Results
Dasatinib in Treating Patients With Previously Treated Malignant Mesothelioma
Condition: Malignant Mesothelioma
Intervention: Drug: dasatinib
5 Completed Gemcitabine and Epirubicin in Treating Patients With Malignant Mesothelioma
Condition: Malignant Mesothelioma
Interventions: Drug: epirubicin hydrochloride;   Drug: gemcitabine hydrochloride
6 Active, not recruiting Pemetrexed Disodium/Observation in Treating Patients W/ Malignant Pleural Mesothelioma w/Out Progressive Disease After 1st Line Chemotherapy
Condition: Malignant Mesothelioma
Interventions: Drug: pemetrexed disodium;   Other: clinical observation
7 Recruiting Nintedanib (BIBF 1120) in Mesothelioma
Condition: Mesothelioma
Interventions: Drug: Nintedanib;   Drug: Pemetrexed;   Drug: Cisplatin;   Drug: Placebo
8 Recruiting Phase Ib Study of Anetumab Ravtansine in Combination With Pemetrexed and Cisplatin in Mesothelin-expressing Solid Tumors
Condition: Medical Oncology
Interventions: Drug: BAY 94-9343;   Drug: Pemetrexed;   Drug: Cisplatin
9 Completed Collecting Tumor Samples From Patients With Gynecological Tumors
Conditions: Borderline Ovarian Clear Cell Tumor;   Borderline Ovarian Serous Tumor;   Cervical Adenocarcinoma;   Cervical Adenosquamous Carcinoma;   Cervical Small Cell Carcinoma;   Cervical Squamous Cell Carcinoma, Not Otherwise Specified;   Childhood Embryonal Rhabdomyosarcoma;   Childhood Malignant Ovarian Germ Cell Tumor;   Endometrioid Stromal Sarcoma;   Gestational Trophoblastic Tumor;   Malignant Mesothelioma;   Malignant Ovarian Epithelial Tumor;   Melanoma;   Neoplasm of Uncertain Malignant Potential;   Ovarian Brenner Tumor;   Ovarian Clear Cell Cystadenocarcinoma;   Ovarian Serous Cystadenocarcinoma;   Paget Disease of the Vulva;   Recurrent Cervical Carcinoma;   Recurrent Fallopian Tube Carcinoma;   Recurrent Ovarian Carcinoma;   Recurrent Ovarian Germ Cell Tumor;   Recurrent Primary Peritoneal Carcinoma;   Recurrent Uterine Corpus Carcinoma;   Recurrent Vaginal Carcinoma;   Recurrent Vulvar Carcinoma;   Stage I Ovarian Cancer;   Stage I Uterine Corpus Cancer;   Stage I Vaginal Cancer;   Stage I Vulvar Cancer;   Stage IA Cervical Cancer;   Stage IA Fallopian Tube Cancer;   Stage IA Ovarian Cancer;   Stage IA Ovarian Germ Cell Tumor;   Stage IB Cervical Cancer;   Stage IB Fallopian Tube Cancer;   Stage IB Ovarian Cancer;   Stage IB Ovarian Germ Cell Tumor;   Stage IC Fallopian Tube Cancer;   Stage IC Ovarian Cancer;   Stage IC Ovarian Germ Cell Tumor;   Stage II Ovarian Cancer;   Stage II Uterine Corpus Cancer;   Stage II Vaginal Cancer;   Stage II Vulvar Cancer;   Stage IIA Cervical Cancer;   Stage IIA Fallopian Tube Cancer;   Stage IIA Ovarian Cancer;   Stage IIA Ovarian Germ Cell Tumor;   Stage IIB Cervical Cancer;   Stage IIB Fallopian Tube Cancer;   Stage IIB Ovarian Cancer;   Stage IIB Ovarian Germ Cell Tumor;   Stage IIC Fallopian Tube Cancer;   Stage IIC Ovarian Cancer;   Stage IIC Ovarian Germ Cell Tumor;   Stage III Borderline Ovarian Surface Epithelial-Stromal Tumor;   Stage III Cervical Cancer;   Stage III Uterine Corpus Cancer;   Stage III Vaginal Cancer;   Stage III Vulvar Cancer;   Stage IIIA Fallopian Tube Cancer;   Stage IIIA Ovarian Cancer;   Stage IIIA Ovarian Germ Cell Tumor;   Stage IIIA Primary Peritoneal Cancer;   Stage IIIB Fallopian Tube Cancer;   Stage IIIB Ovarian Cancer;   Stage IIIB Ovarian Germ Cell Tumor;   Stage IIIB Primary Peritoneal Cancer;   Stage IIIC Fallopian Tube Cancer;   Stage IIIC Ovarian Cancer;   Stage IIIC Ovarian Germ Cell Tumor;   Stage IIIC Primary Peritoneal Cancer;   Stage IV Borderline Ovarian Surface Epithelial-Stromal Tumor;   Stage IV Fallopian Tube Cancer;   Stage IV Ovarian Cancer;   Stage IV Primary Peritoneal Cancer;   Stage IV Uterine Corpus Cancer;   Stage IVA Cervical Cancer;   Stage IVA Vaginal Cancer;   Stage IVB Cervical Cancer;   Stage IVB Vaginal Cancer;   Stage IVB Vulvar Cancer;   Uterine Corpus Cancer;   Uterine Corpus Leiomyosarcoma;   Vulvar Squamous Cell Carcinoma
Intervention: Other: Laboratory Biomarker Analysis
10 Recruiting Study to Evaluate GSK3052230 in Combination With Paclitaxel and Carboplatin, or Docetaxel or as Single Agent in Subjects With Solid Malignancies and Deregulated Fibroblast Growth Factor (FGF) Pathway Signaling
Condition: Cancer
Interventions: Drug: GSK3052230;   Drug: paclitaxel;   Drug: carboplatin;   Drug: docetaxel;   Drug: pemetrexed;   Drug: cisplatin
11 Active, not recruiting LEE011 for Patients With CDK4/6 Pathway Activated Tumors (SIGNATURE)
Condition: Tumors With CDK4/6 Pathway Activation
Intervention: Drug: LEE011
12 Completed PTK787/ZK 222584 in Treating Patients With Unresectable Malignant Mesothelioma
Condition: Malignant Mesothelioma
Intervention: Drug: PTK787/ZK 222584
13 Recruiting Safety Study of MGD009 in B7-H3-expressing Tumors
Conditions: Mesothelioma;   Bladder Cancer;   Melanoma;   Squamous Cell Carcinoma of the Head and Neck;   Non Small Cell Lung Cancer;   Clear Cell Renal Cell Carcinoma;   Ovarian Cancer;   Thyroid Cancer;   Breast Cancer;   Pancreatic Cancer;   Prostate Cancer;   Colon Cancer;   Soft Tissue Sarcoma
Intervention: Biological: MGD009
14 Active, not recruiting Randomized, Double-blind Study Comparing Tremelimumab to Placebo in Subjects With Unresectable Malignant Mesothelioma
Condition: Unresectable Pleural or Peritoneal Malignant Mesothelioma
Interventions: Drug: Tremelimumab;   Drug: Placebo
15 Unknown  S0722: Everolimus in Treating Patients With Pleural Malignant Mesothelioma That Cannot Be Removed By Surgery
Condition: Malignant Mesothelioma
Intervention: Drug: everolimus
16 Recruiting Phase II Anetumab Ravtansine as 2nd Line Treatment for Malignant Pleural Mesothelioma (MPM)
Condition: Mesothelioma
Interventions: Drug: Anetumab ravtansine (BAY 94-9343);   Drug: Vinorelbine
17 Recruiting A Study of BMS-986148 in Patients With Select Advanced Solid Tumors
Condition: Advanced Cancer
Interventions: Drug: BMS-986148;   Biological: Nivolumab

Study has passed its completion date and status has not been verified in more than two years.